Endometrial thickness still presents a best reference to predict endometrial cancer

Li, Yiu‐Tai; Lee, Wen-Ling; Tsui, Kuan‐Hao

doi:10.1016/j.tjog.2015.07.003

Cited by 9 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were confirmed by Long et al in a recent meta-analysis that proposed an endometrial thickness cut-off of ≥ 5 mm as good enough to rule out the presence of EC in patients with AUB [22]. However, different authors raised concerns about an approach based only on ET-specific cut-offs to exclude the presence of EC and our results support these findings [23][24][25].…”

Section: General Considerationssupporting

confidence: 90%

See 1 more Smart Citation

Endometrial Cancer Risk Prediction According to Indication of Diagnostic Hysteroscopy in Post-Menopausal Women

et al. 2020

View full text Add to dashboard Cite

We conducted a prospective observational study investigating the clinical relevance of endometrial thickness (ET) and abnormal uterine bleeding (AUB) on endometrial cancer (EC) risk in a cohort of postmenopausal patients undergoing diagnostic hysteroscopy and endometrial biopsy. Patients were divided into two groups according to the indication of diagnostic hysteroscopy: ET_Group (asymptomatic patients with endometrial thickness ≥ 4 mm) and AUB_Group (patients with a history of abnormal uterine bleeding). We further divided the AUB_Group into two subgroups based on endometrial thickness (AUB_Subgroup1: ET < 4 mm; AUB_Subgroup2: ET ≥ 4 mm). The primary outcome was the risk of endometrial cancer and atypical hyperplasia according to the indications of diagnostic hysteroscopy (AUB, ET ≥ 4 mm or both). The secondary outcome was to determine the best cut-off value of endometrial thickness to predict endometrial cancer in asymptomatic postmenopausal women. The prevalence of endometrial cancer and atypical hyperplasia in AUB_Group and ET_Group was 21% and 6.7% respectively. As well as for EC alone, higher prevalence of both conditions was observed in AUB_Subgroup2 (29.3%) in comparison to AUB_Subgroup1 (10.6%; p < 0.001). In asymptomatic patients the cut-off of endometrial thickness that showed the best sensitivity and specificity to diagnose endometrial cancer (100% and 80% respectively) was 11 mm (AUC of 91.4%; Expβ: 1067; CI 95%). In conclusion, considering the high risk of neoplasia, diagnostic hysteroscopy with endometrial biopsy should be mandatory in cases of abnormal uterine bleeding in postmenopausal patients. Moreover, we want to emphasize the need for further evidence stating the clinical relevance of endometrial thickness value in asymptomatic patients and the impact of individual risk factors on endometrial cancer development.

show abstract

Section: General Considerationssupporting

confidence: 90%

“…Moreover, women with persistent or recurrent bleeding should trigger additional evaluation, such as endometrial sampling and hysteroscopy [8]. A suggestion for further studies could be the use of ET as a tool to define the urgency of EB in women with postmenopausal AUB [23,29].…”

Section: Main Findingsmentioning

confidence: 99%

Endometrial Cancer Risk Prediction According to Indication of Diagnostic Hysteroscopy in Post-Menopausal Women

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer constitutes a malignant tumor that seriously threatens women’s health worldwide. Though its incidence is lower than that of cervical and endometrial cancers, its rate of mortality is highest among all female gynecological tumors [1]. Notably, ovarian cancer exhibits no specific clinical manifestations in the early stage, resulting in the majority of patients presenting with metastasis and invading cancer cells at the time of diagnosis.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities

Chen

Chang

Lin

et al. 2019

IJERPH

Self Cite

105

View full text Add to dashboard Cite

Ovarian cancer comprises one of the three major malignant tumor types in the female reproductive system. The mortality rate of this cancer is the highest among all gynecological tumors, with ovarian cancer metastasis constituting an important cause of death. Therefore, markers for disease prediction and prognosis are highly desirable for early diagnosis as well as for helping optimize and personalize treatment. Recently, microRNAs (miRNAs), which consist of short-sequence RNAs that do not encode a protein, have emerged as new biomarkers in the clinical diagnosis and treatment of ovarian cancer. By pairing with bases specific to the target messenger RNA (mRNA), miRNAs cause degradation of the target mRNA or inhibit its translation, thereby regulating various cellular processes including cell proliferation and adhesion. Increasing numbers of studies have shown that miRNA expression abnormality plays an important role in the development of ovarian cancer. In this review, we discuss the mechanisms of miRNA action, current research regarding their role in the suppression or promotion of ovarian cancer, and their use as markers for diagnosis of prognosis or as therapeutic targets for this disease. Finally, we present future perspectives regarding the clinical management of ovarian cancer and the role for miRNAs therein.

show abstract

“…Generally, endometrial thickness > 4-5 mm in symptomatic postmenopausal women is accepted as pathological [5]. On the other hand, there is no consensus on the endometrial thickness which should be considered pathological in asymptomatic postmenopausal women [6,7]. The criteria for symptomatic patients are often used for these patients too [8].…”

Section: Introductionmentioning

confidence: 99%

False Endometrial Thickening in Postmenopausal Patients Using Anticoagulants or Antiplatelets Agents

Ata

Kulhan

2021

Aegean J Obstet Gynecol

View full text Add to dashboard Cite

Objective There is no report that anticoagulant or antiplatelet use may lead to abnormal endometrial sonographic findings. This retrospective study reports our first results associated with endometrial sampling in asymptomatic postmenopausal women using anticoagulants or antiplatelet. Materials methods A total of 268 postmenopausal patients who applied to our gynecology outpatient clinic for any reasons except postmenopausal bleeding were included in the study. Patients were divided into three groups according to using drug status: first healty control group [HCG], second anticoagulants agents group [ACG], and third antiplatelet agents group [APG]. The effects of anticoagulant and antiplatelet agents on endometrial thickness were compared with histopathological findings. Results The mean endometrial thickness was significantly greater in group ACG [5.2 mm] and APG [4.1 m] than in group HCG [3.3 mm]. No significant differences were found in the mean endometrial thickness between groups HCG and APG. However, it is noteworthy that the average endomeric thickness in the ACG group is more than the other two groups and this is statistically significant [p < 0.05]. Conclusion If the thickness of the endometrium was > 4 mm. endometrial sampling may be recommended in in asymptomatic postmenopausal women using anticoagulants or antiplatelet agents.

show abstract

Endometrial thickness still presents a best reference to predict endometrial cancer

Cited by 9 publications

References 3 publications

Endometrial Cancer Risk Prediction According to Indication of Diagnostic Hysteroscopy in Post-Menopausal Women

Endometrial Cancer Risk Prediction According to Indication of Diagnostic Hysteroscopy in Post-Menopausal Women

MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities

False Endometrial Thickening in Postmenopausal Patients Using Anticoagulants or Antiplatelets Agents

Contact Info

Product

Resources

About